Please wait a minute...
Reviews in Cardiovascular Medicine  2018, Vol. 19 Issue (3): 77-88     DOI: 10.31083/j.rcm.2018.03.908
Treatment Update | Next articles
Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions
Sivakumar Sudhakaran1, 2, 3, 5, Teodoro Bottiglieri2, 3, 4, 5, Kristen M. Tecson2, 3, 4, 5, Aaron Y. Kluger2, 3, 4, 5, Peter A. McCullough1, 2, 3, 4, 5, *()
1 Department of Internal Medicine, Baylor University Medical Center Roberts Hospitals, Suite H-102 3500 Gaston Ave, Dallas, TX 75246 USA
2 Baylor Jack and Jane Hamilton Heart and Vascular Hospital 621 Hall St, Dallas, TX 75226 USA
3 Baylor Heart and Vascular Institute 621 Hall St, Dallas, TX 75226 USA
4 Baylor Kimberly H. Courtwright and Joseph W. Summers Institute of Metabolic Disease Baylor Research Institute at Dallas 3812 Elm Street Dallas, Texas 75226 USA
5 Baylor Scott & White Research Institute at Dallas 3310 Live Oak, Suite 501 Dallas, TX 75204 USA
Download:  PDF(1229KB)  ( 1245 )
Export:  BibTeX | EndNote (RIS)      

The role of anti-hyperlipidemic therapy remains of key importance in the treatment of atherosclerotic disease. Moreover, given an already exaggerated predisposition for vascular disease at baseline, there is a preponderance of data that show management of hyperlipidemia is especially important in patients with chronic kidney disease. This is a concise, up-to-date review of lipid physiology, alterations in lipid concentrations with progressive renal failure, and currently available and emerging hyperlipidemic treatment options. Specifically, the roles of these therapies in patients with chronic kidney disease are reviewed.

Key words:  Hyperlipidemia      chronic kidney disease (CKD)      PCSK9      lipid physiology      hyperlipidemia in CKD      hyperlipidemia management     
Published:  30 September 2018     
*Corresponding Author(s):  Peter A. McCullough,   

Cite this article: 

Sivakumar Sudhakaran, Teodoro Bottiglieri, Kristen M. Tecson, Aaron Y. Kluger, Peter A. McCullough. Alteration of lipid metabolism in chronic kidney disease, the role of novel antihyperlipidemic agents, and future directions. Reviews in Cardiovascular Medicine, 2018, 19(3): 77-88.

URL:     OR

[1] Andrikoula M, and McDowell IF. The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab. 2008;10:271-278.
[2] Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110:2809-2816.
[3] Atthobari J, Brantsma AH, Gansevoort RT, et al. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant. 2006;21:3106-3114.
[4] Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-2192.
[5] Bakris GL. Lipid disorders in uremia and dialysis. Contrib Nephrol. 2012;178:100-105.
[6] Ball T, and McCullough PA. Statins for the prevention of contrastinduced acute kidney injury. Nephron Clin Pract. 2014;127:165-171.
[7] Bhatt DL, Steg PG, Brinton EA, et al. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin Cardiol. 2017;40:138-148.
[8] Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. Circulation. 2015;132:677-690.
[9] Charytan DM, Sabatine, Marc S, et al. Efficacy and Safety of Evolocumab in CKD: Data from the FOURIER Trial. Paper presented at the American Society of Nephrology: Kidney Week, San Diego. 2018.
[10] Chen HY, Dufresne L, Burr H, et al. Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records. JAMA Cardiol. 2018;3:18-23.
[11] Corsini A, Bellosta S, Baetta R, Fumagalli, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
[12] Dominiczak MH, and Caslake MJ. Apolipoproteins: metabolic role and clinical biochemistry applications. Ann Clin Biochem. 2011;48:498-515.
[13] Duranton F, Laget J, Gayrard N, et al. The CKD plasma lipidome varies with disease severity and outcome. J Clin Lipidol. 2019;13:176-185.
[14] Einarsson K, Ericsson S, Ewerth S, et al. Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism. Eur J Clin Pharmacol. 1991;40:S53-S58.
[15] Fares H., Lavie CJ, DiNicolantonio JJ, et al. Icosapent ethyl for the treatment of severe hypertriglyceridemia. Ther Clin Risk Manag. 2014;10:485-492.
[16] Feingold KR, and Grunfeld C. Introduction to Lipids and Lipoproteins. In L. J. De Groot, G. Chrousos, K. Dungan, K. R. Feingold, A. Grossman, J. M. Hershman, C. Koch, M. Korbonits, R. McLachlan, M. New, J. Purnell, R. Rebar, F. Singer, A. Vinik (Eds.), Endotext. South Dartmouth (MA):, Inc. 2000.
[17] Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
[18] Friedman A, and Moe S. Review of the Effects of Omega-3 Supplementation in Dialysis Patients. Clinical Journal of the American Society of Nephrology. 2006;1:182-192.
[19] Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339-352.
[20] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines. 2018;8:S0735-S1097.
[21] Haynes R, Lewis D, Emberson, et al. Effects of lowering LDL cholesterol on progression of kidney disease. J Am Soc Nephrol. 2014;25:1825-1833.
[22] Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009;10:1-7.
[23] Hoover-Plow J, and Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism. 2013;62:479-491.
[24] Jin K, Park BS, Kim YW, et al. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 2014;63:584-589.
[25] Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:2061-2071.
[26] Kamanna VS, and Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101:20b-26b.
[27] Kaysen GA. Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutr. 2009;19:73-77.
[28] KDIGO KDIGOLWG. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl. 2013;3:259-305.
[29] Kimura G, Kasahara M, Ueshima K, et al. Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial. Clin Exp Nephrol. 2017;21:417-424.
[30] Kolski B, and Tsimikas S. Emerging therapeutic agents to lower lipoprotein (a) levels. Curr Opin Lipidol. 2012;23:560-568.
[31] Kotani K, and Banach M. Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9. J Thorac Dis. 2017;9:E78-E82.
[32] Kovesdy CP, Astor BC, Longenecker JC. et al. Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition Examination Survey (1991-1994). Am J Kidney Dis. 2002;40:899-908.
[33] Kronenberg F. Causes and consequences of lipoprotein(a) abnormalities in kidney disease. Clin Exp Nephrol. 2014;18:234-237.
[34] Kronenberg F, Kuen E, Ritz E, et al. (2000). Lipoprotein(a) Serum Concentrations and Apolipoprotein(a) Phenotypes in Mild and Moderate Renal Failure. Journal of the American Society of Nephrology. 2000;11:105-115.
[35] Kronenberg F, Lingenhel A, Lhotta K, et al. Lipoprotein(a)- and lowdensity lipoprotein-derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? Kidney Int. 2004;66:348-354.
[36] Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17-28.
[37] Lin J, Khetarpal SA, Terembula K, et al. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study. BMC Nephrol. 2015;16:2-8.
[38] Litvinov D, Mahini H, Garelnabi M. Antioxidant and antiinflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci. 2012;4:523-532.
[39] Mafham M, and Haynes R. PCSK9 inhibition: ready for prime time in CKD? Kidney Int. 2018;93:1267-1269.
[40] Maqbool F, Safavi M, Bahadar H, et al. Discovery Approaches for Novel Dyslipidemia Drugs. Curr Drug Discov Technol. 2015;12:90-116.
[41] McCullough PA, Ballantyne CM, Sanganalmath SK, et al. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials). Am J Cardiol. 2018;121:940-948.
[42] McCullough PA, Choi JP, Feghali GA, et al. Contrast-Induced Acute Kidney Injury. J Am Coll Cardiol. 2016;68:1465-1473.
[43] Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol. 2011;57:1611-1621.
[44] Mikolasevic I, Zutelija M, Mavrinac V, et al. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35-45.
[45] Morena M, Le May C, Chenine L, et al. Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. J Clin Lipidol. 2017;11:187-193.
[46] Navaneethan SD, Pansini F, Perkovic V, et al. (2009). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;15:Cd007784.
[47] Nicholls SJ, Puri R, Anderso T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Jama. 2016;316:2373-2384.
[48] Okubo K, Ikewaki K, Sakai S, et al. Abnormal HDL Apolipoprotein A-I and A-II Kinetics in Hemodialysis Patients: A Stable Isotope Study. Journal of the American Society of Nephrology. 2004;15:1008-1015.
[49] Ooi EM, Watts GF, Farvid MS, et al. High-density lipoprotein apolipoprotein A-I kinetics in obesity. Obes Res. 2005;13:1008-1016.
[50] Parsons DS, Reaveley DA, Pavitt DV, et al. Relationship of renal function to homocysteine and lipoprotein(a) levels: the frequency of the combination of both risk factors in chronic renal impairment. Am J Kidney Dis. 2002;40:916-923.
[51] Perry CM. (2013). Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13:285-296.
[52] Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med. 1985;312:1210-1216.
[53] Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:1-13.
[54] Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
[55] Rahman M, Baimbridge C, Davis BR, et al. Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis. 2008;52:412-424.
[56] Rahman M, Yang W, Akkina S, et al. Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study. Clin J Am Soc Nephrol. 2014;9:1190-1198.
[57] Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis. 1994;5:81-87.
[58] Ray KK, Bays HE, Catapano AL, et al. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med. 2019;380:1022-1032.
[59] Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489-1499.
[60] Rocha NA, East C, Zhang J, et al. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen. Curr Atheroscler Rep. 2017;19:1-9.
[61] Rogacev KS, Heine GH, Silbernagel G, et al. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS One. 2016;11:1-14.
[62] Rogers MA, and Aikawa E. A Not-So-Little Role for Lipoprotein(a) in the Development of Calcific Aortic Valve Disease. Circulation. 2015;132:621-623.
[63] Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72:314-329.
[64] Ruggenenti P, Perna A, Tonelli M. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual reninangiotensin system blockade: the ESPLANADE trial. Clin J Am Soc Nephrol. 2010;5:1928-1938.
[65] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376:1713-1722.
[66] Sahebkar A, and Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013;27:559-567.
[67] Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116:85-97.
[68] Schmidt RJ, Beyer TP, Bensch WR, et al. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem Biophys Res Commun. 2008;370:634-640.
[69] Sechi LA, Zingaro L, Catena C, et al. Lipoprotein(a) and apolipoprotein( a) isoforms and proteinuria in patients with moderate renal failure. Kidney Int. 1999;56:1049-1057.
[70] Sehayek E, Butbul E, Avner R, et al. Enhanced cellular metabolism of very low density lipoprotein by simvastatin. A novel mechanism of action of HMG-CoA reductase inhibitors. Eur J Clin Invest. 1994;24:173-178.
[71] Sharp Collaborative G. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160:785-794.
[72] Shearer GC, Savinova OV, Harris WS. Fish oil-how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821:843-851.
[73] Shrestha S, Wu BJ, Guiney L, et al. Cholesteryl ester transfer protein and its inhibitors. J Lipid Res. 2018;59:772-783.
[74] Soutar AK, and Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4:214-225.
[75] Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
[76] Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials. BMJ. 2008;336:645-651.
[77] Szarek M, White HD, Schwartz GG, et al. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial. J Am Coll Cardiol. 2018;74:25693.
[78] Thompson A, and Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med. 2006;259:481-492.
[79] Thompson PD, Panza G, Zaleski A, et al. Statin-Associated Side Effects. J Am Coll Cardiol. 2016;67:2395-2410.
[80] Tsimikas S. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes. 2016;23:157-164.
[81] Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69:692-711.
[82] Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebocontrolled phase 1 study. Lancet. 2015;386:1472-1483.
[83] Uhlig K, Wang SR, Beck GJ, et al. Factors associated with lipoprotein(a) in chronic kidney disease. Am J Kidney Dis. 2005;45:28-38.
[84] Vavilis G, Bäck M, Occhino G, et al. Kidney Dysfunction and the Risk of Developing Aortic Stenosis. J Am Coll Cardiol. 2019;73:305-314.
[85] Verdoodt A, Honore PM, Jacobs R, et al. Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018. J Transl Int Med. 2018:6;21-25.
[86] Wang X, Collins HL, Ranalletta M, et al. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest. 2007;117:2216-2224.
[87] Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-248.
[88] Wen CP, Cheng TY, Tsai, MK, et al. (2008). All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet. 2008;371:2173- 2182.
[89] Zhang J, Bottiglieri T, McCullough PA. The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. Cardiorenal Med. 2017;7:104-117.
[90] Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339-345.
[1] Kui Huang, Xiao-Qin Wen, Ning Ren, Li Yang, Bo Gao. Lipidomic profile in patients with a very high risk of atherosclerotic cardiovascular disease on PCSK9 inhibitor therapy[J]. Reviews in Cardiovascular Medicine, 2021, 22(2): 461-467.
[2] Jennifer G. Robinson, Karol E. Watson. Identifying Patients for Nonstatin Therapy[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 1-8.
[3] Jennifer G. Robinson, Karol E. Watson. Can We Cure Atherosclerosis?[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 20-24.
[4] Seth J. Baum, Alan S. Brown. Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 25-30.
[5] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31-46.
[6] Seth J. Baum, Daniel Soffe, P. Barton Duell. Emerging Treatments for Heterozygous and Homozygous Familial Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2016, 17(1-2): 16-27.
[7] Norman E. Lepor, Laurn Contreras, Chirag Desai, Dean J. Kereiakes. The Potential Role of Anti-PCSK9 Monoclonal Antibodies in the Management of Hypercholesterolemia[J]. Reviews in Cardiovascular Medicine, 2014, 15(4): 290-309.
[8] Divya Ratan Verma, Eliot A. Brinton. Management of Hypercholesterolemia for Prevention of Atherosclerotic Cardiovascular Disease: Focus on the Potential Role of Recombinant Anti-PCSK9 Monoclonal Antibodies[J]. Reviews in Cardiovascular Medicine, 2014, 15(2): 86-101.
[9] . Best of the ACC Scientific Session 2001[J]. Reviews in Cardiovascular Medicine, 2001, 2(3): 143-159.
No Suggested Reading articles found!